| ID | TICKER | DATE | Notes To Know | Time | Broker Rating |
|---|---|---|---|---|---|
| 1 | UROV | 05/05/2019 | Urovant Sciences to present theapies at the American Urological Associatiomeeting in Chicago | 2:10 pm ET | Cowen Outperform $25 PT JPM Overweight $24 PT SuntTrust Buy $23 PT |
| 2 | NVS | 05/05/2019 | Phase 3 commencement of dosing announced April 25, 2018.Data at AAN May 5, 2019, 11:30 AM.Completion 2021. | Credit Suisse Outperform $66 PT Guggenheim Buy $86 PT | |
| 3 | PGNX | 06/05/2019 | Phase 2/3 data to be presented at AUA May 6, 2019.Phase 3 data due early 2020. | Needham Buy $10 PT | |
| 4 | MNOV | 06/05/2019 | Phase 2b top-line data released October 28, 2017. Primary endpoint met.Additional data to be presented at AAN meeting May 6, 2019 at 2:06 PM ET. | B.Riley Buy $22 PT | |
| 5 | RARX | 07/05/2019 | Phase 2 trial met endpoints-December 10, 2018.Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019. | Raymond James Outperform $49 PT Stifel Buy $48 PT | |
| 6 | GWPH | 07/05/2019 | Phase 2 trial met endpoints-December 10, 2018.Data to be presented at AAN May 7, 2019, 11:30 a.m. Phase 3 trial to commence 2H 2019. | Oppenheimer Perform $162 PT Piper Overweight $185 PT | |
| 7 | BHVN | 07/05/2019 | Phase 3 data to be presented at AAN in late-breaker May 7, 2019. | Leerink Outperform $67 PT Oppenheimer Outperform $70 PT Cannaccord Buy $80 PT | |
| 8 | DRRX | 07/05/2019 | Phase 2/3 data to be presented at AAN May 7, 2019. 1pm. To report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its earnings after the close | ||
| 9 | BIIB | 07/05/2019 | Phase 1/2 data to be presented at AAN in late-breaker May 7, 2019.Phase 3 data due 2H 2020. | Pipper Overweight $280 PT RBC Sector Perform $234 PT Cannaccord Neutral $275 PT | |
| 10 | OVID | 07/05/2019 | Phase 1/2 data to be presented at AAN in late-breaker May 7,2019.Phase 3 data due 2H 2020. | Cantor Overweight $7.00 PT Pipper Overweight $14.00PT | |
| 11 | PTCT | 07/05/2019 | Phase 2/3 data to be presented at AAN May 7, 2019. 1pm. | Bernstein Outperform $47 PT | |
| 12 | CATB | 09/05/2019 | Phase 3 data due 2Q 2020.Phase 1/2 data to be presented at AAN May 9,2019. | ||
| 13 | QURE | 10/05/2019 | Phase 2b 26-week follow-up data to be presented at HTRS May 10,2019. | Piper Overweight $80 PT | |
| 14 | SESN | 13/05/2019 | PDUFA date for sBLA May 13,2019. | ||
| 15 | REGN | 13/05/2019 | PDUFA date for sBLA May 13, 2019. | Jefferies Hold $343 PT | |
| 16 | AMGN | 15/05/2019 | Phase 1 data due at ASCO June 3,2019, 9am. | BMO Outperform $229 Jefferies Buy $230 | |
| 17 | MRTX | 17/05/2019 | Phase 1/2 update due 2H 2019.On watch for potential impact from release of ASCO abstract for AMGN 510 on May 15,2019. | DA Davidson Neutral $22 | |
| 18 | ACHN | 17/05/2019 | Phase 2 interim data due May 17,2019. | Barclays Underweight $2.50 | |
| 19 | MDCO | 18/05/2019 | Phase 2 open-label data to be presented at National Lipid Association Scientific Sessions on May 18, 2019. | Goldman Buy $54 | |
| 20 | BMY | 20/05/2019 | The FDA determined at that time, that the submission of this new information constituted a major amendment to the Sbla and extended the review. | JPM Overweight $59 PT Barclays Overweight $55 PT | |
| 21 | ATHX | 20/05/2019 | Phase 2a data released January 23,2019.Data to be presented at ATS, May 20,2019.Phase 2 ONE-BRIDGE commencement of enrolment announced. | ||
| 22 | LLY | 20/05/2019 | Phase 2 data due at DDW meeting 18-21 May,2019 | BMO Capital Outperform $133 PT Edward Jones Buy $116 PT | |
| 23 | PIRS | 22/05/2019 | Phase 1 initial data due at ATS meeting May 22,2019 1:30pm. | ||
| 24 | INCY | 24/05/2019 | PDUFA date under priority review extended by three months to May 24,2019. | Barclays Equaweight $82PT Stifel Hold $92PT | |
| 25 | NVS | 24/05/2019 | PDUFA date under priority review extended by three months to May 24,2019. | Guggenheim Buy $86 PT | |
| 26 | CNCE | 28/05/2019 | Phase 1 data to be presented at ASCP May 28-31,2019. | Stifel Buy $18 PT Mizuho Buy $23 PT |